Highlights Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Real-time Estimate Cboe BZX Other stock markets 11:35:50 09/05/2024 pm IST			5-day change	1st Jan Change
1.285 ^USD	-8.21%		-0.77%	+4.03%

01:23pm	Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M	MT
23/04	Averoa Seeks EU Approval for Chronic Kidney Disease Drug	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M	04:53pm	MT
Averoa Seeks EU Approval for Chronic Kidney Disease Drug	23/04	MT
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	16/04	CI
Akebia Shares Rally Premarket After FDA Approves Vafseo	28/03	DJ
U.S. FDA approves Akebia's anemia drug	28/03	RE
U.S. FDA approves Akebia's anemia drug	28/03	RE
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	28/03	CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M	15/03	MT
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	15/03	CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03	CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q3 Revenue $42M	08/11	MT
Akebia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Akebia Therapeutics Says FDA Accepts Vadadustat Resubmission	25/23/25	MT
Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023	18/23/18	CI
Akebia Therapeutics Resubmits New Drug Application to US FDA for Vadadustat	28/23/28	MT
Akebia Therapeutics Says Australia Approves Anemia Oral Drug Vafseo	27/23/27	MT
Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023	26/23/26	CI
Akebia Therapeutics, Inc. Announces Approval of Vafseo® in Australia	26/23/26	CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q2 Revenue $56.4M	25/23/25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Highlights

Filters